With disease-modifying compounds targeting alpha-synuclein available in clinical trials, patient stratification according to alpha-synuclein-specific enrichment strategies is a much-needed prerequisite. Such a scenario will be exemplified for GBA, one major genetic risk factor that is specifically associated with the alpha-synucleinopathies: Parkinson’s disease and dementia with Lewy bodies.

中文翻译：

---

GBA相关的突触核蛋白病：α-突触核蛋白靶向化合物的主要候选人。

临床试验中有针对α-突触核蛋白的疾病缓解化合物，根据α-突触核蛋白特异性富集策略进行患者分层是非常需要的先决条件。这种情况将被举例说明大湾区，这是一种专门与α-突触核蛋白病相关的主要遗传危险因素：帕金森氏病和路易体痴呆。